0.791
-0.01 (-0.63%)
| Previous Close | 0.796 |
| Open | 0.841 |
| Volume | 1,018,705 |
| Avg. Volume (3M) | 673,703 |
| Market Cap | 1,811,825,408 |
| Price / Sales | 914.87 |
| Price / Book | 97.15 |
| 52 Weeks Range | |
| Earnings Date | 17 Mar 2025 |
| Operating Margin (TTM) | -67,856.58% |
| Diluted EPS (TTM) | -0.620 |
| Total Debt/Equity (MRQ) | 0.81% |
| Current Ratio (MRQ) | 10.93 |
| Operating Cash Flow (TTM) | -126.35 M |
| Levered Free Cash Flow (TTM) | -121.36 M |
| Return on Assets (TTM) | -25.87% |
| Return on Equity (TTM) | -41.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ProKidney Corp. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 2.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -4.0 |
| Average | 0.38 |
|
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 28.29% |
| % Held by Institutions | 44.35% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Mar 2025 | Announcement | ProKidney Reports Full Year 2024 Financial Results and Business Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |